A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer

Part of paid clinical trials in Beverly Hills, California.

Sponsor
MBQ Pharma
Study ID
NCT06075810
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
21 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • MBQ-167 — DRUG
    MBQ-167, an inhibitor of Rho GTPases Rac and Cdc42

Study Details

A Phase 1, open-label, dose-escalation clinical trial of MBQ-167 in participants with advanced Breast Cancer for whom Standard of Care (SOC) has failed or has proven intolerable.

Key Dates

Start date
Nov 9, 2023
Status verified
Dec 2024
Primary completion
Oct 1, 2025
Completion
Oct 31, 2025

Study Design

Enrollment
48 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: MBQ-167 oral capsule
    A dose ranging from 10mg to 400mg BID following a standard 3+3 cohort design

Primary Outcome Measure

Maximum Tolerated Dose (MTD) [ Time Frame: 21 days ]

Central Contacts

Locations (3)

FacilityCityStateZIPSite coordinators
Precision Next Gen Oncology & Research CenterBeverly HillsCalifornia90212
Rebecca Godin
[email protected]
424-777-0708
Francisco Capilla
[email protected]
424-777-0708
Kumar Sankhala, MD (PRINCIPAL_INVESTIGATOR)
Florida Cancer Specialists / Sarah Cannon Research Institute / SCRISarasotaFlorida34232
Judy S Wang, MD
[email protected]
941-377-9993
Judy S Wang, MD (PRINCIPAL_INVESTIGATOR)
Sarah Cannon Research Institute/SCRINashvilleTennessee37203
Melissa Sindler
[email protected]
844-482-4812
Denise Yardley, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Beverly Hills, CA

By condition
Breast cancer
By specialty
OncologyBreast oncologyWomen's health
By research site
Precision Next Gen Oncology & Research Center· Beverly Hills, CAFlorida Cancer Specialists / Sarah Cannon Research Institute / SCRI· Sarasota, FLSarah Cannon Research Institute/SCRI· Nashville, TN

Related Studies